Icotrokinra

Icotrokinra is a synthetic, orally bioavailable macrocyclic peptide developed by Johnson & Johnson (Janssen) in collaboration with Protagonist Therapeutics, a company specializing in peptide drug discovery. It represents a new pharmacological category for psoriasis treatment: rather than an injectable monoclonal antibody neutralizing a cytokine, icotrokinra is a small, orally-dosed peptide that binds the IL-23 receptor on immune cells directly.

The FDA approved icotrokinra (brand name Icotyde) in March 2026 for moderate-to-severe plaque psoriasis in adults and adolescents 12 and older weighing at least 40 kg, making it the first oral IL-23-pathway therapy to reach approval — a category previously limited to injectable antibodies (risankizumab, guselkumab) or the broader p40-blocking ustekinumab.

Approval was supported by the Phase 3 ICONIC program, including ICONIC-LEAD (adults and adolescents) and ICONIC-ADVANCE 1 & 2, which used deucravacitinib as an active comparator in addition to placebo — a notably rigorous trial design for a psoriasis therapy, and one that let icotrokinra demonstrate statistical superiority over an existing oral option rather than just placebo.

Its structural class is itself notable: a macrocyclic peptide built from both natural and non-canonical amino acids, cyclized via a disulfide bond, engineered for oral stability and receptor selectivity that peptide drugs have historically struggled to achieve without injection.

// IL-23 RECEPTOR ANTAGONISM

Icotrokinra binds directly to the extracellular ligand-binding domain of the IL-23 receptor (IL-23R) itself — not the IL-23 cytokine — acting as a competitive antagonist. Reported binding affinity is in the low picomolar range (KD ≈ 7.1 pM against human IL-23R), with a comparably potent IC50 for blocking IL-23-induced STAT3 phosphorylation in human immune cells.

// DOWNSTREAM PATHWAY BLOCKADE

By occupying the receptor, icotrokinra prevents IL-23 from triggering JAK2/TYK2 → STAT3 signaling, which in turn reduces downstream production of IL-17A, IL-17F, IL-22, and IFN-γ — the effector cytokines that drive psoriatic skin inflammation.

// IL-12 SPARING SELECTIVITY

Unlike ustekinumab, which blocks the p40 subunit shared by both IL-12 and IL-23, icotrokinra is selective for the IL-23 receptor and does not measurably affect IL-12-driven STAT4 signaling even at very high concentrations — a selectivity profile similar to the newer injectable IL-23p19 antibodies, but achieved orally.

// ORAL DELIVERY AS A MACROCYCLIC PEPTIDE

Its macrocyclic structure, combining natural and non-canonical amino acids, is specifically engineered for enough metabolic stability to survive oral dosing while retaining high-affinity receptor binding — a structural approach the peptide-drug-discovery field has pursued for years to bring antibody-like target specificity to a pill.

ICONIC-LEAD (Phase 3, adults and adolescents): at week 16, PASI 90 response was reported at roughly 50% for icotrokinra vs. ~4% for placebo; by week 24, roughly 65% reached PASI 90. In the adolescent cohort, 86% reached PASI 90 by week 52. These percentages are drawn from secondary press/medical-news coverage rather than the raw published trial paper — treat as directionally reliable pending direct confirmation against the primary publication.

ICONIC-ADVANCE 1 & 2 (Phase 3, active-comparator design): compared against deucravacitinib (an oral TYK2 inhibitor) in addition to placebo, across two trials totaling roughly 1,500 adult participants. Icotrokinra reportedly demonstrated statistical superiority over deucravacitinib at weeks 16 and 24 on complete-clearance (IGA 0) and PASI 100 endpoints. Exact figures should be verified against the primary Lancet publication before being treated as final.

Safety across trials was reported as similar to placebo in overall adverse-event rates, with headache, nausea, cough, and fungal infection among the most common adverse reactions (each in the low single-digit percentages). No boxed warning was identified in sources reviewed, though this was not independently verified against the raw FDA label text.

Open items: exact amino acid residue count/sequence, and precise trial efficacy percentages, should be confirmed against primary sources (PMC11289455 for preclinical pharmacology; the ICONIC-ADVANCE Lancet paper for trial data) before being cited as exact figures elsewhere on the site.